Literature DB >> 12721767

Inhibition of early 99mTc-MIBI uptake by Bcl-2 anti-apoptotic protein overexpression in untreated breast carcinoma.

Silvana Del Vecchio1, Antonella Zannetti, Luigi Aloj, Corradina Caracò, Andrea Ciarmiello, Marco Salvatore.   

Abstract

Lack of technetium-99m methoxyisobutylisonitrile ((99m)Tc-MIBI) uptake is consistently reported to predict poor response to subsequent chemotherapy in a variety of human malignant tumours. Since (99m)Tc-MIBI accumulates within mitochondria, which also play a central role in apoptosis through the integration of death signals by Bcl-2 family members, we tested whether early (99m)Tc-MIBI uptake is affected by alterations of the apoptotic pathway. Forty-two breast cancer patients were intravenously injected with 740 MBq of (99m)Tc-MIBI and planar images were obtained 10 min post injection with the patients in the prone lateral position. Ten carcinomas failed to accumulate (99m)Tc-MIBI and could not be visualised on scintigraphic images despite being larger than 1.8 cm (MIBI negative). Thirty-two of the 42 breast carcinomas showed focal uptake of (99m)Tc-MIBI (MIBI positive), and 10 min tumour-to-background ratios (T/B) varied between 1.14 and 6.93. The apoptotic index, the rate of proliferation, and the expression of the anti-apoptotic Bcl-2 protein and pro-apoptotic Bax protein were assessed in surgically excised tumours. All MIBI-negative carcinomas showed a dramatic and statistically significant reduction in the apoptotic index as compared with MIBI-positive lesions (mean+/-SD, 0.14+/-0.15 vs 1.28+/-0.83, P<0.0001) independently of rate of proliferation, tumour size and P-glycoprotein expression. Significantly higher levels of Bcl-2 were also found in MIBI-negative as compared with MIBI-positive carcinomas. In MIBI-positive lesions, an inverse significant correlation was found between T/B ratios and Bcl-2 levels ( r=-0.50, P<0.01). Our findings indicate that early uptake of (99m)Tc-MIBI in breast carcinomas is affected by alterations of apoptotic pathway. High levels of Bcl-2, despite the stabilisation of mitochondrial membrane potentials, prevent accumulation of (99m)Tc-MIBI in tumour cells. In conclusion, absent or reduced early (99m)Tc-MIBI uptake in large tumours may indicate a Bcl-2-mediated resistance to chemo- and radiotherapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12721767     DOI: 10.1007/s00259-003-1161-x

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  37 in total

Review 1.  Mitochondria as the central control point of apoptosis.

Authors:  S Desagher; J C Martinou
Journal:  Trends Cell Biol       Date:  2000-09       Impact factor: 20.808

2.  Bcl-2 prevents apoptotic mitochondrial dysfunction by regulating proton flux.

Authors:  S Shimizu; Y Eguchi; W Kamiike; Y Funahashi; A Mignon; V Lacronique; H Matsuda; Y Tsujimoto
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

3.  Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked.

Authors:  J Yang; X Liu; K Bhalla; C N Kim; A M Ibrado; J Cai; T I Peng; D P Jones; X Wang
Journal:  Science       Date:  1997-02-21       Impact factor: 47.728

4.  Fractional retention of technetium-99m-sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients.

Authors:  S Del Vecchio; A Ciarmiello; L Pace; M I Potena; M V Carriero; C Mainolfi; R Thomas; G D'Aiuto; T Tsuruo; M Salvatore
Journal:  J Nucl Med       Date:  1997-09       Impact factor: 10.057

5.  Prediction of chemotherapeutic response by Technetium 99m--MIBI scintigraphy in breast carcinoma patients.

Authors:  Y Takamura; Y Miyoshi; T Taguchi; S Noguchi
Journal:  Cancer       Date:  2001-07-15       Impact factor: 6.860

6.  The apoptosis-necrosis paradox. Apoptogenic proteases activated after mitochondrial permeability transition determine the mode of cell death.

Authors:  T Hirsch; P Marchetti; S A Susin; B Dallaporta; N Zamzami; I Marzo; M Geuskens; G Kroemer
Journal:  Oncogene       Date:  1997-09-25       Impact factor: 9.867

Review 7.  Dysregulation of apoptosis in cancer.

Authors:  J C Reed
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

8.  Technetium-99m-MIBI uptake in small cell lung cancer.

Authors:  H S Bom; Y C Kim; H C Song; J J Min; J Y Kim; K O Park
Journal:  J Nucl Med       Date:  1998-01       Impact factor: 10.057

9.  Evaluation of therapy response in children with untreated malignant lymphomas using technetium-99m-sestamibi.

Authors:  L O Kapucu; C Akyüz; G Vural; A Oguz; T Atasever; M Büyükpamukçu; M Unlü
Journal:  J Nucl Med       Date:  1997-02       Impact factor: 10.057

10.  Technetium-99m-sestamethoxyisobutylisonitrile scan as a predictor of chemotherapy response in malignant lymphomas compared with P-glycoprotein expression, multidrug resistance-related protein expression and other prognosis factors.

Authors:  C H Kao; S C Tsai; J J Wang; Y J Ho; S T Ho; S P Changlai
Journal:  Br J Haematol       Date:  2001-05       Impact factor: 6.998

View more
  8 in total

1.  Nuclear medicine in the treatment of neuroendocrine tumours--problems and perspectives.

Authors:  Tomasz Grzela; Agata Bialoszewska; Robert Brawura-Biskupski-Samaha
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-04       Impact factor: 9.236

2.  Prediction of the response to docetaxel-based chemotherapy for locoregionally advanced nasopharyngeal carcinoma: the role of double-phase (99m)Tc-MIBI SPECT/CT.

Authors:  Chengrun Du; Hongmei Ying; Junjun Zhou; Jinjin Jiang; Chang Liu; Jingyi Chen; Xiaosheng Wang; Chaosu Hu
Journal:  Med Oncol       Date:  2014-01-09       Impact factor: 3.064

3.  (99m)Tc-sestamibi scintigraphy used to evaluate tumor response to neoadjuvant chemotherapy in locally advanced breast cancer: A quantitative analysis.

Authors:  Katia Hiromoto Koga; Sonia Marta Moriguchi; Jorge Nahás Neto; Stela Verzinhasse Peres; Eduardo Tinóis DA Silva; Almir José Sarri; Odair Carlito Michelin; Mariangela Esther Alencar Marques; Beatriz Lotufo Griva
Journal:  Oncol Lett       Date:  2010-03-01       Impact factor: 2.967

4.  To use MIBI or not to use MIBI? That is the question when assessing tumour cells.

Authors:  Jean-Luc Moretti; Nathalie Hauet; Meltem Caglar; Olivier Rebillard; Zeynep Burak
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-07       Impact factor: 9.236

5.  Bcl-2 overexpression prevents 99mTc-MIBI uptake in breast cancer cell lines.

Authors:  Luigi Aloj; Antonella Zannetti; Corradina Caracó; Silvana Del Vecchio; Marco Salvatore
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-12-10       Impact factor: 9.236

Review 6.  99mTc-MIBI in the evaluation of breast cancer biology.

Authors:  Silvana Del Vecchio; Marco Salvatore
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-04-23       Impact factor: 9.236

7.  Predicting early chemotherapy response with technetium-99m methoxyisobutylisonitrile SPECT/CT in advanced non-small cell lung cancer.

Authors:  Tzu-I J Yang; Tjeerd S Aukema; Harm van Tinteren; Sjaak Burgers; Renato Valdés Olmos; Marcel Verheij
Journal:  Mol Imaging Biol       Date:  2009-09-12       Impact factor: 3.488

8.  Effect of trifluoperazine on Tc-99m sestamibi uptake in patients with advanced nonsmall cell lung cancer.

Authors:  Ümmühan Abdülrezzak; Zeynep Erdoğan; Güler Silov; Ayşegül Özdal; Özgül Turhal
Journal:  Indian J Nucl Med       Date:  2016 Apr-Jun
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.